Menu

Rare Genetic Disease: Models and Mechanisms

The Scientist is bringing together a panel of experts to share their research, and to highlight the challenges and advantages in utilizing specific model organisms.

Oct 1, 2019
The Scientist Creative Services Team

FREE Webinar

Tuesday, November 19, 2019
2:30 - 4:00  PM Eastern Time

Register Now

Establishing research models for any human disease is tricky business - more so for rare genetic diseases such as ataxia, telangiectasia, progeria, Paget’s disease, and Rett syndrome. Researchers focused on model organisms such as Caenorhabditis elegans, Drosophila, mice, zebrafish, and yeast rarely connect with clinicians who report a rare genetic disease. Yet, studies on model organisms have provided pivotal insights into the mechanisms of several rare genetic diseases. For a detailed discussion on insights gained from model organisms used in understanding a wide spectrum of rare genetic diseases, The Scientist is bringing together a panel of experts to share their research, and to highlight the challenges and advantages in utilizing specific model organisms. Attendees will learn how model organisms can be utilized to parse complex mechanisms underlying rare genetic disease from renowned experts in our interactive setting.

Topics to be Covered

  • Modeling Rett syndrome using mice
  • Tanks to bedside: examples of disease modeling in zebrafish

Register Now

Meet the Speakers:

Monica Justice, PhD
Program Head and Senior Scientist
Genetics & Genome Biology Program, SickKids Research Institute
Professor of Molecular Genetics, University of Toronto
Scientific Director, The Centre for Phenogenomics

Shawn Burgess, PhD
Senior Investigator
Head, Developmental Genomics Section
National Human Genome Research Institute
National Institutes of Health

November 2019

Oceanic Connections

Biologists consider the movements of marine animals

Marketplace

Sponsored Product Updates

Diagenode to Offer Single-Cell ATAC-Seq Services Featuring Bio-Rad’s Droplet Digital PCR Technology
Diagenode to Offer Single-Cell ATAC-Seq Services Featuring Bio-Rad’s Droplet Digital PCR Technology
Diagenode, Inc., a leading global provider of solutions for epigenetics research and sample preparation, and Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb), a global leader in life science research and clinical diagnostic products, today announced a partnership in which Diagenode will offer Single-Cell ATAC-Seq (scATAC-Seq) Services, featuring Bio-Rad’s Droplet Digital PCR technology, to help advance epigenomics research.
Bio-Rad Introduces EveryBlot Blocking Buffer that Offers 5-Minute Blocking Time and Greater Sensitivity for Western Blots
Bio-Rad Introduces EveryBlot Blocking Buffer that Offers 5-Minute Blocking Time and Greater Sensitivity for Western Blots
Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb) today announced the launch of EveryBlot Blocking Buffer, a western blot blocking reagent that offers 5-minute blocking time and produces higher signal and lower background levels resulting in greater sensitivity for western blots compared to other available blocking buffers.
TTP plc Desktop Biology enables development and manufacture of DnaNudge technology
TTP plc Desktop Biology enables development and manufacture of DnaNudge technology
·        Novel multiplex technology developed to help consumers make healthier choices based on their genetic profile·        TTP involved with all aspects of product development, from initial concept to prototype testing and manufacture·        Culmination of technology and product development partnership spanning just over 3 years
Targos and Ultivue partner to incorporate highly standardized UltiMapper™ tissue multiplex phenotypic assays in support of clinical research services
Targos and Ultivue partner to incorporate highly standardized UltiMapper™ tissue multiplex phenotypic assays in support of clinical research services
Targos Molecular Pathology GmbH, a market leader in clinical biomarker services announced today a technology partnership with Ultivue, the innovation leader in multiplex tissue biomarker assays, to offer the biopharmaceutical industry new capabilities to improve the characterization of cancer patients’ samples selected for clinical research programs.